View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
August 12, 2021updated 11 Jul 2022 9:50am

More virtual trial content posted by digital pharma influencers since Covid-19 began

Clinical trial disruption during lockdowns has increased interest in virtual trials, with more online content being published.

By GlobalData Healthcare

Covid-19 lockdowns and social distancing measures caused significant disruption to clinical trials and accelerated the use of virtual trials. Companies that had not considered this model before the pandemic had no option but to rapidly implement new technologies and procedures to maintain business continuity. As a result, there has been increased interest in the virtual trial space, as shown by increased online content and discussions on social media.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

For example, an analysis of the Clinical Trials trend on GlobalData’s Digital Pharma Influencer Database shows that the most dominant themes from last January to this April are related to digital technology and Covid-19. These themes include ‘Digital Health’, ‘Covid-19’, ‘Healthtech’, ‘Mhealth’, ‘Wearables’, ‘Medical Technologies’, ‘Virtual Trials’, ‘Decentralised’, ‘Telehealth’, ‘Telemedicine’, ‘Virtual Care’, ‘Remote Patient Monitoring’, ‘RPM’ and ‘Smart Watches’. From last March to last July, there was an increase in terms related to Covid-19, remote patient monitoring, wearable technology, telehealth, telemedicine and decentralised and virtual trials, which is in line with the disruption seen to trials as a result of the pandemic (Figure 1).

Many posts related to clinical trial innovation have been made by leading digital health experts, such as John Nosta, Daniel Kraft, Bertalan Meskó and virtual trial pioneer Craig Lipset. The top posts in this time period discussed the impact of Covid-19 on the acceleration of virtual trials, the advantages of virtual trials, and information about the Decentralised Trials and Research Alliance.

The current, traditional clinical trial model is outdated and the shift toward virtual trials was already underway before the Covid-19 pandemic began. Virtual trials use digital technologies that differ from traditional trial models to bring research closer to patients’ homes and improve their experience by reducing or even eliminating the number of physical site visits required. This leads to improved patient recruitment and retention rates, as well as reduced timelines and costs for sponsors. Research shows that Covid-19 accelerated this trend and suggests that many companies will continue to use or implement virtual trials after the pandemic.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology